The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single-institution phase II trial of radiation (RT), temozolomide (TMZ), erlotinib, and bevacizumab for initial treatment of glioblastoma (GBM).
Jennifer Leigh Clarke
No relevant relationships to disclose
Annette M Molinaro
No relevant relationships to disclose
Nicholas A. Butowski
Honoraria - Genentech
Susan Marina Chang
No relevant relationships to disclose
Joanna J Phillips
No relevant relationships to disclose
Bruno M Costa
No relevant relationships to disclose
Joseph F Costello
No relevant relationships to disclose
Jane E Rabbitt
No relevant relationships to disclose
Valerie A Kivett
No relevant relationships to disclose
Ashley A DeSilva
No relevant relationships to disclose
Michael Prados
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Expert Testimony - Genentech (U)